Naghitorabi Mojgan, Mir Mohammad Sadeghi Hamid, Mohammadi Asl Javad, Rabbani Mohammad, Jafarian-Dehkordi Abbas
Department of Pharmacognosy, School of Pharmacy, Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran.
Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Pharm Res. 2017 Spring;16(2):771-780.
Promoter methylation is one of the main epigenetic mechanisms that leads to the inactivation of tumor suppressor genes during carcinogenesis. Due to the reversible nature of DNA methylation, many studies have been performed to correct theses epigenetic defects by inhibiting DNA methyltransferases (DNMTs). In this case novel therapeutics especially siRNA oligonucleotides have been used to specifically knock down the DNMTs at mRNA level. Also many studies have focused on transcriptional gene silencing in mammalian cells via siRNA mediated promoter methylation. The present study was designed to assess the role of siRNA mediated promoter methylation in DNMT3B knockdown and alteration of promoter methylation of Cadherin-1 (CDH1), Glutathione S-Transferase Pi 1(GSTP1), and DNMT3B genes in MDA-MB-453 cell line. MDA-MB-453 cells were transfected with siDNMT targeting DNMT3B promoter and harvested at 24 and 48 h post transfection to monitor gene silencing and promoter methylation respectively. DNMT3B expression was monitored by quantitative RT-PCR method. Promoter methylation was quantitatively evaluated using differential high resolution melting analysis. A non-significant 20% reduction in DNMT3B mRNA level was shown only after first transfection with siDNMT, which was not reproducible. Promoter methylation levels of DNMT3B, CDH1, and GSTP1 were detected at about 15%, 70% and 10% respectively, in the MDA-MB-453 cell line, with no significant change after transfection. Our results indicated that siDNMT sequence were not able to affect promoter methylation and silencing of DNMT3B in MDA-MB-453 cells. However, quantitation of methylation confirmed a hypermethylated phenotype at CDH1 and GSTP1 promoters as well as a differential methylation pattern at DNMT3B promoter in breast cancer.
启动子甲基化是致癌过程中导致肿瘤抑制基因失活的主要表观遗传机制之一。由于DNA甲基化具有可逆性,许多研究致力于通过抑制DNA甲基转移酶(DNMTs)来纠正这些表观遗传缺陷。在这种情况下,新型疗法尤其是小干扰RNA(siRNA)寡核苷酸已被用于在mRNA水平特异性敲低DNMTs。此外,许多研究聚焦于通过siRNA介导的启动子甲基化实现哺乳动物细胞中的转录基因沉默。本研究旨在评估siRNA介导的启动子甲基化在MDA-MB-453细胞系中敲低DNMT3B以及改变钙黏蛋白-1(CDH1)、谷胱甘肽S-转移酶Pi 1(GSTP1)和DNMT3B基因启动子甲基化方面的作用。用靶向DNMT3B启动子的siDNMT转染MDA-MB-453细胞,并在转染后24小时和48小时收获细胞,分别监测基因沉默和启动子甲基化情况。通过定量逆转录-聚合酶链反应(RT-PCR)方法监测DNMT3B的表达。使用差异高分辨率熔解分析法定量评估启动子甲基化。仅在首次用siDNMT转染后,DNMT3B mRNA水平出现了不显著的20%下降,且无法重复。在MDA-MB-453细胞系中,DNMT3B、CDH1和GSTP1的启动子甲基化水平分别约为15%、70%和10%,转染后无显著变化。我们的结果表明,siDNMT序列无法影响MDA-MB-453细胞中DNMT3B的启动子甲基化和沉默。然而,甲基化定量证实乳腺癌中CDH1和GSTP1启动子存在高甲基化表型,以及DNMT3B启动子存在差异甲基化模式。